ÂÜÀòÂÒÂ×

Ruben is a co-founder and Chief Executive Officer of Polyneuron. His drug discovery expertise, including chemical synthesis, assay development, compound screening, profiling and in vivo pharmacology led him to co-develop the anti-MAG neuropathy drug candidate PN-1007. He is an expert in the underlying core technology Antibody-Catchâ„¢. Ruben holds an M.Sc. and Ph.D. in Pharmaceutical Sciences from the University of Basel.